Recent advances in the therapy of renal cancer

Bibliography

• JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56:106-130.
   PubMed Web of Science ®Google Scholar
• FYFE G, FISHER RI, ROSENBERG SA, SZNOL M, PARKINSON DR, LOUIE AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. (1995) 13:688-696.
   PubMed Web of Science ®Google Scholar
• FISHER RI, ROSENBERG SA, SZNOL M, PARKINSON DR, FYFE G: High-dose aldesleukin in renal cell carcinoma: long-term survival update [see comments]. Cancer J. Sci. Am. (1997) 3(Suppl. 1):S70-S72.
   PubMed Web of Science ®Google Scholar
• NEGRIER S, ESCUDIER B, LASSET C et al.: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d’Immunotherapie. N. Engl. J. Med. (1998) 338:1272-1278.
   PubMed Web of Science ®Google Scholar
• YANG JC, SHERRY RM, STEINBERG SM et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21:3127-3132.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT DF, REGAN MM, CLARK JI et al.: Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2005) 23(1):133-141.
   PubMed Web of Science ®Google Scholar
• BUI MH, SELIGSON D, HAN KR et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. (2003) 9(2):802-811.
   PubMed Web of Science ®Google Scholar
• ATKINS M, REGAN M, MCDERMOTT D et al.: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. (2005) 11(10):3714-3721.
   PubMed Web of Science ®Google Scholar
• UPTON MP, PARKER RA, YOUMANS A et al.: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J. Immunother. (2005) 28(5):488-495.
   PubMed Web of Science ®Google Scholar
• COPPIN C, PORZSOLT F, KUMPF J et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (2000) (3):CD001425.
   Google Scholar
• NO AUTHORS LISTED: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet (1999) 353(9146):14-17.
   PubMed Web of Science ®Google Scholar
• PYRHONEN S, SALMINEN E, RUUTU M et al.: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. (1999) 17(9):2859-2867.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, BACIK J, MURPHY BA et al.: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. (2002) 20(1):289-296.
   PubMed Web of Science ®Google Scholar
• FLANIGAN RC, SALMON SE, BLUMENSTEIN BA et al.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. (2001) 345:1655-1659.
   PubMed Web of Science ®Google Scholar
• MICKISCH GH, GARIN A, VAN POPPEL H et al.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (2001) 358:966-970.
   PubMed Web of Science ®Google Scholar
• PANTUCK AJ, BELLDEGRUN AS, FIGLIN RA: Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N. Engl. J. Med. (2001) 345(23):1711-1712.
   PubMed Web of Science ®Google Scholar
• STADLER WM, HALABI S, RINI B et al.: A Phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer (2006) 107(6):1273-1279.
   PubMed Web of Science ®Google Scholar
• GEORGE CM, STADLER WM: The role of systemic chemotherapy in the treatment of kidney cancer. In: Kidney Cancer. Figlin R (Ed.), Kluwer Academic Publishers, Norwell, MA, USA (2003).
   Google Scholar
• COHEN HT, MCGOVERN FJ: Medical progress: renal-cell carcinoma. N. Engl. J. Med. (2005) 353:2477-2490.
   PubMed Web of Science ®Google Scholar
• HICKLIN DJ, ELLIS LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. (2005) 23:1011-1027.
   PubMed Web of Science ®Google Scholar
• HILGER RA, SCHEULEN ME, STRUMBERG D: The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie (2002) 25:511-518.
   PubMed Web of Science ®Google Scholar
• CHEN J, FUJII K, ZHANG L et al.: Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc. Natl. Acad. Sci. USA (2001) 98:7783-7788.
   PubMed Web of Science ®Google Scholar
• ALAVI A, HOOD JD, FRAUSTO R et al.: Role of Raf in vascular protection from distinct apoptotic stimuli. Science (2003) 301:94-96.
   PubMed Web of Science ®Google Scholar
• CHEN J, FUJII K, ZHANG L et al.: Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc. Natl. Acad. Sci. USA (2001) 98:7783-7788.
   PubMed Web of Science ®Google Scholar
• HUDSON CC, LIU M, CHIANG GG et al.: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. (2002) 22:7004-7014.
   PubMed Web of Science ®Google Scholar
• MITA MM, MITA A, ROWINSKY EK: The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther. (2003) 2:S169-S177.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, MAZUMDAR M, BACIK J et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. (1999) 17(8):2530-2540.
   PubMed Web of Science ®Google Scholar
• MEKHAIL TM, ABOU-JAWDE RM, BOUMERHI G et al.: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. (2005) 23(4):832-841.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, BACIK J, SCHWARTZ LH et al.: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2004) 22:454-463.
   PubMed Web of Science ®Google Scholar
• ZISMAN A, PANTUCK AJ, DOREY F et al.: Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. (2001) 19:1649-1657.
   PubMed Web of Science ®Google Scholar
• NEGRIER S, ESCUDIER B, GOMEZ F et al.: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann. Oncol. (2002) 13:1460-1468.
   PubMed Web of Science ®Google Scholar
• MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Clin. Cancer Res. (2003) 9:327-337.
   PubMed Web of Science ®Google Scholar
• FAIVRE S, DELBALDO C, VERA K et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. (2006) 24:25-35.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, MICHAELSON MD, REDMAN BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24:16-24.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, RINI BI, BUKOWSKI RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295:2516-2524.
   PubMed Web of Science ®Google Scholar
• RINI BI, GEORGE DJ, MICHAELSON MD et al.: Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2006) 24:222s (Abstract 4522).
   Google Scholar
• MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2006) 24:2s (Abstract LBA3).
   Google Scholar
• GIBBONS JJ, DISCAFANI C, PETERSON R: The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract 1000]. Proc. Am. Assoc. Cancer Res. (1999) 40:301.
   Google Scholar
• ATKINS MB, HIDALGO M, STADLER WM et al.: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. (2004) 22:909-918.
   PubMed Web of Science ®Google Scholar
• SMITH JW, KO Y-J, DUTCHER J et al.: Update of a Phase I study of intravenous CCI-779 given in combination with interferon-alpha to patients with advanced renal cell carcinoma [abstract 4513]. Proc. Am. Assoc. Cancer Res. (2004) 23:384.
   Google Scholar
• HUDES G, CARDUCCI M, TOMCZAK P et al.: A Phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line poor-prognosis patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2006) 24:2s (Abstract LBA4).
   Google Scholar
• WILHELM SM, CARTER C, TANG L et al.: BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. (2004) 64:7099-7109.
   PubMed Web of Science ®Google Scholar
• STRUMBERG D, RICHLY H, HILGER RA et al.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. (2005) 23:965-972.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, HIRTE HW, SIU L et al.: Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann. Oncol. (2005) 16:1688-1694.
   PubMed Web of Science ®Google Scholar
• RATAIN MJ, EISEN T, STADLER WM et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24:2505-2512.
   PubMed Web of Science ®Google Scholar
• ESCUDIER B, SZCZYLIK C, EISEN T et al.: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. Eur. J. Cancer Suppl. (2005) 3:226 (Abstract 794).
   Google Scholar
• EISEN T, BUKOWSKI RM, STAEHLER M et al.: Randomized Phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. 2006 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 24(18 Suppl.):4524.
   Google Scholar
• ESCUDIER B, SZCZYLIK C, DEMKOW T et al.: Randomized Phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2006) 24(18S):4501.
   Google Scholar
• RYAN CW, GOLDMAN BH, LARA PN JR et al.: Sorafenib plus interferon-alpha2b as first-line therapy for advanced renal cell carcinoma: SWOG 0412. Proc. Am. Soc. Clin. Oncol. (2006) 24:223s (Abstract 4525).
   Web of Science ®Google Scholar
• GOLLOB J, RICHMOND T, JONES J et al.: Phase II trial of sorafenib plus interferon-alpha 2b (IFN-a2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). 2006 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 24(18S):4538.
   Google Scholar
• SOSMAN JA, FLAHERTY K, ATKINS MB et al.: A Phase I/II trial of sorafenib with bevacizumab in metastatic renal cell cancer patients. Proc. Am. Soc. Clin. Oncol. (2006) 24:128s (Abstract 3031).
   Web of Science ®Google Scholar
• AZAD NS, POSADAS EM, KWITKOWSKI VE et al.: Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. 2006 ASCO Annual Meeting Proceedings (2006) J. Clin. Oncol. 24(18S):3004.
   Web of Science ®Google Scholar
• TAMASKAR I, SHAHEEN P, WOOD L et al.: Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2006) 24(18S):4597.
   Google Scholar
• YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349:427-434.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, SOSMAN JA, SPIGEL DR et al.: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. (2005) 23:7889-7896.
   PubMed Web of Science ®Google Scholar
• BUKOWSKI RM, KABBINAVAR F, FIGLIN RA et al.: Bevacizumab with or without erlotinib. J. Clin. Oncol. (2006) Proc. Am. Soc. Clin. Oncol. 24(18S):Abstract 4523.
   PubMedGoogle Scholar
• RUGO HS, HERBST RS, LIU G et al.: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. (2005) 23:5474-5483.
   PubMed Web of Science ®Google Scholar
• RINI B, RIXE O, BUKOWSKI R et al.: AG-013736, a multitarget tyrosine kinase receptor inhibitor, demonstrates antitumor activity in a Phase II study of cytokine-refractory, metastatic renal cell cancer. J. Clin. Oncol. (2005) 23(Pt I, Suppl.):Abstract 4509.
   Google Scholar
• RAVAUD A, GARDNER J, HAWKINS R et al.: Efficacy of lapatinib in patients with high tumor EGFR expression: results of a Phase III trial in advanced renal cell carcinoma (RCC). 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2006) 24(18S):4502.
   Google Scholar
• HURWITZ H, DOWLATI A, SAVAGE S et al.: Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2005) 23(16 Suppl., Part I of II):3012.
   Web of Science ®Google Scholar
• SUTTLE AB, HURWITZ H, DOWLATI A et al.: Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. (2004) 22(14 Suppl.):3054.
   Google Scholar
• CHOUEIRI TK, DREICER R, RINI BI et al.: Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2006) 24(18S):4539
   PubMed Web of Science ®Google Scholar
• GEORGE D, MICHAELSON D, OH WK: Phase I study of PTK787/ZK222584 (PTK/ZK) in metastatic renal cell carcinoma [abstract 1548]. Proc. Am. Soc. Clin. Oncol. (2003) 22:385.
   Google Scholar
• DUPONT J, ROTHENBERG ML, SPRIGGS DR et al.: Safety and pharmacokinetics of intravenous VEGF Trap in a Phase I clinical trial of patients with advanced solid tumors. J. Clin. Oncol. (2005) 23(16S):3029.
   Google Scholar
• FIGLIN RA, KONDAGUNTA GV, YAZJI S et al.: Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC). 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2006) 24(18S):4535.
   Google Scholar
• BLEUMER I, KNUTH A, OOSTERWIJK E et al.: A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer (2004) 90(5):985-990.
   PubMed Web of Science ®Google Scholar
• BLEUMER I, OOSTERWIJK E, OOSTERWIJK-WAKKA JC et al.: A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J. Urol. (2006) 175(1):57-62.
   PubMed Web of Science ®Google Scholar
• UEMURA H, FUJIMOTO K, TANAKA M et al.: A Phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin. Cancer Res. (2006) 12(6):1768-1775.
   PubMed Web of Science ®Google Scholar